PFA pdf
Awaiting price reaction for this filing.
Nutraplus India Ltd has filed its quarterly financial results for Q1 FY2022 (quarter ended June 30, 2022) with a significant delay of over 2 years, on October 16, 2024. The auditor issued a Qualified Limited Review Report due to the company's failure to comply with listing requirements and provide timely financial data. Revenue from operations was merely Rs 0.36 lakhs, down from Rs 178.55 lakhs in the previous corresponding period. The company reported a net loss of Rs 0.84 lakhs for the quarter and Rs 370.37 lakhs for the full year FY2022. Note 5 reveals that the company lost ALL its property, plant, and equipment under the SARFAESI Act, 2002, after being declared a Non-Performing Asset in FY 2019-20. COVID-19 delayed the bank's auction process. The company operates in the Active Pharmaceutical Ingredient (API) segment.
This filing reveals extreme financial distress — the company lost all its operating assets, has negligible revenue, and carries massive accumulated losses. The qualified auditor opinion and delayed filing signal serious governance and going concern issues. Shareholders should be aware that the company may not be a viable going concern.